Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ivana Jaqueline Tapia"'
Autor:
Ezequiel Lacunza, Virginia Judith Wolos, Gabriel L. Fiszman, Ivana Jaqueline Tapia, Elisa Bal de Kier Joffé, Marianela Abrigo
Publikováno v:
Cancer Research. 81:1078-1078
Trastuzumab and trastuzumab emtansine (T-DM1) targeted therapies are the main choice for the treatment of HER2-overexpressing breast cancer patients. However, de novo or acquired resistance is still the major obstacle in clinical practice. It has bee
Autor:
José Mordoh, Gabriela Andrea Pizzurro, Leonardo Sganga, Osvaldo L. Podhajcer, Ivana Jaqueline Tapia, Maria Marcela Barrio
Publikováno v:
Cancer Immunology, Immunotherapy. 64:1393-1406
Dendritic cells (DCs) are professional APCs used for the development of cancer vaccines because of their ability to activate adaptive immune responses. Previously, we designed the DC/Apo-Nec vaccine using human DCs loaded with dying melanoma cells th
Autor:
Irene Larripa, María Sol Ruiz, Michele Bianchini, M. Medina, Jose Mordoh, Ivana Jaqueline Tapia, Nicholas C.P. Cross
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Leukemia
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Leukemia
Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the BCR-ABL1 fusion gene in peripheral white blood cells. This analysis is b
Publikováno v:
BMC Cancer
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Background: Hormonal treatment might affect the immune response to tumor antigens induced in cancer patients who are being vaccinated. Case presentation: A 33 years-old woman was diagnosed with cutaneous melanoma in May 2009. Her melanoma was located